ArticleScientific reports2025
CTLA-4 expression on tregs is needed for suppression of autoimmune uveitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immunophenotyping of Human Regulatory T-Cells from Peripheral Blood Mononuclear Cells.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Infection control in the brain and the eye.Acta ophthalmologica · 2026Review
- Research Progress on the Regulatory Role of Treg Cells in Inflammatory Eye Diseases.Current issues in molecular biology · 2026Review
- Regulatory T cell dysfunction and exhaustion in uveitis: immunometabolic mechanisms, microenvironmental drivers, and emerging therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Uveitis is a leading cause of blindness in the world and autoimmune uveitis is an ocular tissue specific autoimmune disease. Utilizing experimental autoimmune uveitis (EAU), we can interrogate different immune responses in the mouse that are relevant to the human disease. cytotoxic T-lymphocyte antigen 4 (CTLA-4) is an immune checkpoint molecule that has different roles depending on the target tissue. In this work we investigate the role of CTLA-4 on CD4 T cells in ocular tissue during EAU. We find that CTLA-4 is needed for both the severity of disease but also timely resolution of disease. Regulatory T cells (Tregs) that emerge in the spleen during resolution of EAU require CTLA-4 to suppress disease, but ocular Tregs that emerge in the eye do not require CTLA-4 to suppress disease. This report provides an additional understanding of CTLA-4 on Tregs that is specific for ocular tissue. The implications of this work are that circulating Tregs in uveitis patients may require CTLA-4 to suppress ocular inflammation but once in the eye the function of CTLA-4 is dispensable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.